Mayne Pharma | MYX - 应收帐款人



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 206.73M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 212.07M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


应收帐款人 更改 日
Ansell USD 231.1M 15.4M 2025-12
Avita Medical AUD 9.11M 2.26M 2025-12
Cochlear AUD 568.4M 17.5M 2025-12
CSL USD 4.32B 1.35B 2025-12
Healius AUD 144.6M 43.1M 2024-12
Integral Diagnostics AUD 24.82M 10.78M 2024-06
Medical Developments International AUD 7.48M 174K 2025-12
Nanosonics AUD 46.45M 8.2M 2025-12
Polynovo AUD 24.21M 945K 2025-12
Ramsay Health Care AUD 2.48B 22.3M 2025-12
ResMed USD 1.05B 88.62M 2025-12
Sigma Healthcare AUD 2.56B 2.23B 2025-12
Sonic Healthcare AUD 1.39B 23.76M 2024-12
Telix Pharmaceuticals AUD 135.24M 5.72M 2025-12